Cost-Effectiveness of SGLT2 Inhibitors in the Management of Type 2 Diabetes

Abstract

Sodium–glucose cotransporter-2 inhibitors confer cardiovascular and renal protection in type 2 diabetes. Using a Markov model over a lifetime horizon, we found SGLT2 inhibitors to be cost-effective compared with standard therapy at commonly accepted willingness-to-pay thresholds, particularly among patients with established cardiovascular disease or chronic kidney disease. Results were robust in sensitivity analyses but sensitive to drug pricing and uptake. These findings support broader reimbursement policies for guideline-directed SGLT2 therapy.